Frank Mühlenbeck

LBBW Venture Capital invests in companies located in DACH region. The firm targets companies operating in the fields of disruptive information technology, life sciences, software, digital formation and fintech. It provides financing for seed and early stage capital requirements with an investment size up to EUR 3 million.

EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept.

Develops cell-permeable RNAi pro-drugs

Discovers and develops antibody-based therapeutic drugs

Calibrium Private Invt invests in small and middle market companies located in the United States, Austria, Germany and Switzerland. The firm targets companies operating in the fields of healthcare, consumer products, information technology, energy and business services. It provides financing for early and buyout transactions.